Neurotech International (NTI) is preparing to start the world’s first clinical trial to assess full spectrum medicinal cannabis in children with Autism Spectrum Disorder.
The company told the ASX 20 paediatric patients aged between 5 and 17 will take part in the 16-week study, which follows successful in vitro studies demonstrating the efficacy of several NTI/Dolce cannabis strains to treat neurological disorders.
NTI has also begun discussions with the Therapeutic Goods Administration for the registration of its full spectrum <0.3% THC medicinal cannabis strains.
MGC Pharma has received an order of around A$1 million from European nutraceuticals producer and distributor Swiss PharmaCan (SPC) for its Covid-19 supplement ArtemiC Rescue.
It is the second major wholesale order received by the company for ArtemiC Rescue under an exclusive agreement with SPC signed in February 2021.
MGC Pharma said it has manufacturing capacity at its Slovenia production facility to produce ArtemiC Rescue on a commercial scale as a food supplement for distribution by SPC.
UPDATE (May 7, 2021): MGC Pharma has entered a trading halt on the ASX ahead of the release of an announcement regarding further findings on ArtemiC. The halt will remain in place until the start of normal trading on Monday, May 10 or until an announcement is released to the market.
Creso Pharma has reported a first quarter revenue rise of 237% on the preceding quarter.
The company said the surge reflected the growing demand for its products as regulatory changes unlock growth opportunities around the world.
It added the proposed acquisition of psychedelics company Halucenex Life Sciences will provide it with first-mover advantage in the space and make it the first 100%-owned psychedelic medicines company listed on the ASX.
Non-executive chairman Adam Blumenthal said: “This quarter marked Creso’s evolution into a broader-based pharmaceutical company.”
Zelira Therapeutics has launched its HOPE range of autism spectrum disorder products in Washington DC through a partnership with licensed manufacturer and distributor Alternative Solutions LLC.
Washington DC has reciprocity with 32 US states with approved medicinal cannabis programs, giving patients registered in those states access to the HOPE range as they can legally purchase the products at an approved dispensary in DC.
Ecofibre has told the ASX its US independent pharmacy business Ananda Professional achieved its best month in April since September 2020.
The company expects to record a loss of $1.5 million for the second half of the year, contributing to an overall forecasted loss of around $7 million for FY21.
CEO Eric Wang said: “Since the middle of March we have seen a good return to growth in our core independent pharmacy channel as COVID-related disruptions subside. We look forward to Ananda Health revenues returning to pre-COVID levels in due course.”